Edesa Biotech, Inc. (EDSA) SEC Filings

Edesa Biotech, Inc. (EDSA) has a new large shareholder group reported on Schedule 13G. Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly report beneficial ownership of 953,739 Edesa common shares, representing 6.9% of the class.

The position consists of 703,739 common shares plus warrants to acquire an additional 250,000 common shares, subject to a 9.99% beneficial ownership limitation. The percentage is based on 13,503,723 common shares outstanding immediately after an offering, as reported in a prospectus dated August 20, 2026. Voting and dispositive power over the 953,739 shares is shared among the Stonepine entities and Plexico, and the Partnership holds the stock for the benefit of its investors.

Edesa Biotech, Inc. (EDSA) received an amended Schedule 13D (Amendment No. 11) from Dr. Pardeep Nijhawan and related entities updating their beneficial ownership in the company’s common shares.

Dr. Nijhawan is reported as the beneficial owner of 2,613,492 common shares, representing approximately 16.31% of Edesa’s outstanding common shares, including shares held directly, through options, restricted share units, warrants, and preferred shares, as well as through several Ontario entities and a family trust. The filing is based on 14,193,356 common shares outstanding as of August 25, 2026, plus specified derivative securities deemed outstanding for this holder. The amendment also notes that since the prior amendment, Dr. Nijhawan received 3,378 restricted share units on July 2, 2026 and 5,324 restricted share units on August 3, 2026, each vesting in full upon grant and issued in lieu of partial salary.

Edesa Biotech, Inc. (EDSA) is the subject of an amended Schedule 13D/A filed by Velan Capital–affiliated entities following an underwritten public offering on August 21, 2026. The Velan Master, Horizon and Opportunity II funds acquired additional common shares and warrants in the transaction.

Velan Master purchased 445,100 Shares and 445,100 New Warrants for $2,448,050, and Velan Horizon purchased 9,445 Shares and 9,445 New Warrants for $51,948. Overall, Velan Capital and related reporting persons may be deemed to beneficially own 1,356,455 Shares, or 9.99% of the class, based on 13,503,723 Shares outstanding plus certain convertible Preferred Shares, subject to ownership caps. The New Warrants are exercisable into an equal number of Shares at $7.50 per Share, until the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06, and are subject to a 9.99% Warrant Ownership Limitation. Without the Ownership Limitation and Warrant Ownership Limitation, the group states it would collectively beneficially own 4,694,923 Shares, or 27.8% of the outstanding Shares.

Edesa Biotech, Inc. (EDSA) entered into an underwriting agreement with Guggenheim Securities for a primary underwritten, registered offering of (i) 3,870,500 common shares with accompanying common share warrants and (ii) pre-funded warrants to purchase up to 675,000 common shares with accompanying common share warrants. Each common share plus warrant unit is priced at $5.50, and each pre-funded warrant plus warrant unit at $5.4999.

The common share warrants have a $7.50 exercise price and expire on the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06. Gross proceeds are expected to be about $25.0 million and net proceeds about $23.1 million, with a 30‑day underwriters’ option for up to 681,825 additional shares and warrants. Edesa plans to use proceeds for general corporate purposes, including working capital, capital expenditures, and research and development and manufacturing expenses.

Edesa Biotech, Inc. (EDSA) is conducting a follow‑on offering of 3,870,500 common shares and, for certain investors in lieu of shares, pre‑funded warrants to purchase up to 675,000 common shares, together with common share warrants to purchase up to 4,545,500 common shares.

The securities are priced at a combined public offering price of $5.50 per common share and accompanying warrant (or $5.4999 per pre‑funded warrant and accompanying warrant), for total gross proceeds of $25.0 million and underwriting discounts of $1.5 million. Estimated net proceeds are about $23.1 million, to be used for general corporate purposes including working capital, R&D and manufacturing.

The common share warrants are exercisable at $7.50 per share and expire on the earlier of 18 months after issuance or 30 days following public announcement of Phase 2 vitiligo topline data for EB06. The pre‑funded warrants are immediately exercisable at $0.0001 per share and do not expire. The offering will dilute new investors by $3.28 per share relative to the $5.50 offering price.

Edesa Biotech, Inc. (EDSA) plans a primary offering of common shares, pre-funded warrants and common share warrants under an effective shelf registration. Each common share (or pre-funded warrant) will be sold together with an accompanying common share warrant, with all securities issued separately but purchased together.

The company expects to use net proceeds for general corporate purposes, including working capital, capital expenditures, and research and development and manufacturing expenses. As of June 30, 2026, Edesa Biotech had 9,633,223 common shares outstanding and net tangible book value of $6.9 million, or $0.72 per share, and discloses that investors in this offering will experience dilution relative to this book value.

Edesa Biotech, Inc. reported larger losses for the quarter and nine months ended June 30, 2026 while advancing its inflammatory and immune‑related drug pipeline. Net loss was $5.4 million for the quarter and $11.9 million for the nine months, compared with $1.7 million and $5.0 million in the prior‑year periods, driven mainly by higher research and development spending on vitiligo candidate EB06 and respiratory candidate paridiprubart.

R&D expenses rose to $3.96 million in the quarter and $7.85 million year‑to‑date, while cash used in operating activities increased to $7.2 million for the nine months. Edesa ended the period with $10.3 million in cash and cash equivalents, working capital of $6.9 million, and an accumulated deficit of $77.9 million. The company disclosed a material uncertainty about its ability to continue as a going concern and expects existing resources, potential ATM sales, and Canadian SRF reimbursements will not fund operations, including the vitiligo program, through fiscal 2026 without additional financing.

Edesa highlighted progress in its pipeline, including regulatory readiness for a Phase 2 EB06 vitiligo study and prior positive Phase 3 data for paridiprubart in ARDS. It also benefits from up to C$23 million in partially repayable Canadian government Strategic Response Fund support and recently raised capital via ATM sales and a June 2026 private placement.

Edesa Biotech, Inc. reported fiscal third-quarter 2026 results and business updates. The company completed preparations for a Phase 2 clinical study of EB06 for moderate-to-severe vitiligo and began activating investigational sites after quarter-end, with initial recruitment expected in Canada, followed by additional jurisdictions subject to regulatory approvals.

In its respiratory program, exploratory analyses in ARDS patients with concurrent acute kidney injury associated paridiprubart plus standard of care with mortality reductions and improvements in the kidney-specific MAKE30 composite endpoint, and Edesa is evaluating regulatory pathways and strategic options. Financially, total operating expenses for the quarter rose to $5.5 million from $1.9 million a year earlier, driven mainly by higher R&D spending on EB06 and increased general and administrative costs. Net loss for the quarter widened to $5.4 million, or $0.60 per share, from $1.7 million, or $0.25 per share. For the nine months ended June 30, 2026, net loss was $11.9 million versus $5.0 million in the prior-year period. At June 30, 2026, Edesa held $10.3 million in cash and cash equivalents and reported working capital of $6.9 million.

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. Chief Executive Officer and 10% owner Pardeep Nijhawan received a grant of 5,324 restricted share units on 2026-08-03, vesting in full upon grant under the 2019 Equity Incentive Compensation Plan. After this award, he directly holds 893,386 common shares, plus additional indirect holdings through affiliated entities and a family trust, for which he disclaims beneficial ownership beyond his pecuniary interest.